Click HERE to view a PDF copy of Dr. Ridgway's CV

Dr. Harry Ridgway is CSO and founder of THERAmolecular, LLC located in southwest New Mexico - USA. He is an independent research scientist and Adjunct Professor, Victoria University, Institute for Sustainable Industry and Liveable Cities, Melbourne, Australia.

For more than a decade he has been engaged in computational drug discovery and design (CADD) research for corporate and academic clients worldwide. Dr. Ridgway holds undergraduate and doctoral degrees in microbiology (chemistry minor) from San Diego State University and UC San Diego’s Scripps Institute of Oceanography. He conducted postdoctoral studies in molecular biology and environmental microbiology at the San Diego and Irvine campuses of the University of California. Prior to his work in drug discovery, Dr. Ridgway was Biotechnology Research Director at Orange County Water District in southern California where he and his team conducted groundbreaking studies of bacterial adhesion and biofilm interactions with desalination membrane materials. In 2002 he was the 9th recipient of the prestigious Clarke Water Prize for contributions made in water science and technology.

His current research at THERAmolecular is focused on the design of safe and effective therapeutics targeting hypertension, addiction, depression and related neurological disorders, such as Parkinson's Disease. With a robust record of academic achievement and publications working at the crossroads of computational drug discovery and molecular modeling of functional nanoporous materials, Dr. Ridgway supports organizations around the globe in achieving their research visions.